全文获取类型
收费全文 | 314372篇 |
免费 | 18581篇 |
国内免费 | 461篇 |
专业分类
耳鼻咽喉 | 4424篇 |
儿科学 | 10658篇 |
妇产科学 | 10714篇 |
基础医学 | 48003篇 |
口腔科学 | 7933篇 |
临床医学 | 26101篇 |
内科学 | 59045篇 |
皮肤病学 | 6660篇 |
神经病学 | 22739篇 |
特种医学 | 12538篇 |
外国民族医学 | 43篇 |
外科学 | 49412篇 |
综合类 | 7890篇 |
现状与发展 | 1篇 |
一般理论 | 162篇 |
预防医学 | 20955篇 |
眼科学 | 7527篇 |
药学 | 22133篇 |
中国医学 | 843篇 |
肿瘤学 | 15633篇 |
出版年
2021年 | 2492篇 |
2019年 | 2545篇 |
2018年 | 3967篇 |
2017年 | 2955篇 |
2016年 | 3418篇 |
2015年 | 3860篇 |
2014年 | 5078篇 |
2013年 | 7940篇 |
2012年 | 10054篇 |
2011年 | 10446篇 |
2010年 | 6807篇 |
2009年 | 6177篇 |
2008年 | 9670篇 |
2007年 | 10588篇 |
2006年 | 10443篇 |
2005年 | 10035篇 |
2004年 | 9566篇 |
2003年 | 9051篇 |
2002年 | 8639篇 |
2001年 | 13520篇 |
2000年 | 13811篇 |
1999年 | 11623篇 |
1998年 | 3210篇 |
1997年 | 2944篇 |
1996年 | 2774篇 |
1995年 | 2693篇 |
1994年 | 2459篇 |
1992年 | 8417篇 |
1991年 | 8550篇 |
1990年 | 8361篇 |
1989年 | 8154篇 |
1988年 | 7396篇 |
1987年 | 7158篇 |
1986年 | 6793篇 |
1985年 | 6600篇 |
1984年 | 4866篇 |
1983年 | 4209篇 |
1982年 | 2571篇 |
1979年 | 4517篇 |
1978年 | 3303篇 |
1977年 | 2814篇 |
1976年 | 2567篇 |
1975年 | 2889篇 |
1974年 | 3423篇 |
1973年 | 3418篇 |
1972年 | 3183篇 |
1971年 | 2998篇 |
1970年 | 2896篇 |
1969年 | 2626篇 |
1968年 | 2584篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
5.
6.
7.
8.
9.
10.
Loss‐of‐function mutations in the gene encoding filaggrin underlie a Japanese family with food‐dependent exercise‐induced anaphylaxis
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)